Publication date: Jun 18, 2019
Dr. Hussein Tawbi on Efficacy and Safety Results From the CheckMate 204 Melanoma Trial Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases. Patients with bilateral uveal melanoma, especially when coincident with remote systemic cancers or a family history of cancer, should be evaluated for germlineBAP1 mutation. Lifelong monitoring for related systemic malignancies is advised. Ocul Oncol Pathol Brain metastases are the most common intracranial tumours and occur in 20-40% of all cancer patients. Lung cancer, breast cancer, and melanoma are the most frequent primary cancer to develop brain metastases. Anatomical magnetic resonance imaging (MRI) of the tumour (in particular post-Gadolinium T1-weighted and T2-weighted FLAIR) provide information about lesion morphology and structure, and are routinely used in clinical practice for both detection and treatment resp. .. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases. The structure of the lead compound and the regions for SAR Conclusions: FBY BNCT provides excellent control over the growth of B16F10 melanoma cancer. Moreover, FBY holds great potential for being an efficient theranostic agent for imaging guided BNCT for the brain tumor, the lung and the liver metastases by offering a possible solution of measuring local boron concentration via PET imaging.
|disease||DOID||central nervous system tumors|
|disease||MESH||central nervous system tumors|